Here’s why the Creso Pharma (ASX:CPH) share price is leaping 9% today

The legal global cannabis market is forecast for further growth.

| More on:
A white cannabis leaf set against a green background with a graph going up, indicating a rising share price for ASX cannabis shares

Image source: Getty Images

The Creso Pharma Ltd (ASX: CPH) share price is surging today, up 9% in morning trade.

Below we take a look at the latest acquisition news that appears to be stoking interest in the ASX cannabis share.

What acquisition was reported?

The Creso Pharma share price is leaping higher after the company reported that it has entered into an asset purchase agreement for the purchase of brand and product portfolio assets owned by ImpACTIVE.

Canadian life sciences company, ImpACTIVE, is focused on CBD-based products offering anti-inflammatory relief to professional and amateur athletes.

Creso said it will acquire the ImpACTIVE Assets through a newly incorporated Creso subsidiary, Creso ImpACTIVE Ltd. Creso will pay C$200,000 (AU$217,000) in Creso Shares, valued at 11 Australian cents per share. That’s below the current Creso Pharma share price of 12 cents.

The acquisition is intended to increase Creso’s CBD offerings in the North American markets. With the ImpACTIVE products containing less than 0.3% THC (the active ingredient in cannabis that gets people “high”), the company said this will “significantly” reduce global regulatory issues.

Commenting on the deal, Creso’s executive VP of North America, Will Lay said:

This acquisition marks the first phase of Creso Pharma’s efforts to enter into the US and I am excited to be working with ImpACTIVE to integrate them into the group. We have instituted aggressive sales targets, which is expected to lead to an increase in Creso Pharma’s top line and increased its market share across North America.

Non-executive chairman, Adam Blumenthal added:

We expect that ImpACTIVE’s range of innovative products and brand ambassadors which will provide Creso Pharma with direct access to an emerging subsection of the global CBD market. The group also has established relationships with major US retail groups, which is expected to provide leverage for Creso Pharma as it seeks to grow sales of its own hemp based CBD products.

Creso Pharma share price snapshot

The Creso Pharma share price has been a stellar performer over the past 12 months, up a whopping 283%. That compares to a gain of 22% posted by the All Ordinaries Index (ASX: XAO) over the last full year.

Over the past month, Creso Pharma shares have gained 5%.

Should you invest $1,000 in Creso Pharma right now?

Before you consider Creso Pharma, you'll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Creso Pharma wasn't one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Cannabis Shares